TJG IS INDEXED IN SCI-EXPANDED AND PUBMED IMPACT FACTOR: 1.4
Turkish Journal of Gastroenterology
  1. Home
  2. Immunosuppressive therapy and ...
Review

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Bilgehan Aygen 1 , Ahmet Muzaffer Demir 2 , Mahmut Gümüş 3 , Oğuz Karabay 4 , Sabahattin Kaymakoğlu 5 , Aydın Şeref Köksal 6 , İftihar Köksal 7 , Necati Örmeci 8 , Fehmi Tabak 9
1.

Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey

2.

Division of Hematology, Department of Internal Diseases, Trakya University School of Medicine, Edirne, Turkey

3.

Division of Oncology, Department of Internal Diseases, İstanbul Medeniyet University School of Medicine, İstanbul, Turkey

4.

Department of Infectious Diseases and Clinical Microbiology & Institute of Medical Sciences, Sakarya University, Sakarya, Turkey

5.

Division of Gastroenterology, Department of Internal Diseases, İstanbul University İstanbul School of Medicine, İstanbul, Turkey

6.

Department of Gastroenterology, Sakarya University School of Medicine, Sakarya, Turkey

7.

Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University School of Medicine, Trabzon, Turkey

8.

Department of Gastroenterology, Ankara University İbn-i Sina Hospital, Ankara, Turkey

9.

Department of Infectious Diseases and Clinical Microbiology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey

Turk J Gastroenterol 2018; 29: 259-269
DOI: 10.5152/tjg.2018.18263
Keywords : Hepatitis B, immunosuppressive therapy, reactivation risk, antiviral prophylaxis
Read: 3974 Downloads: 1447 Published: 25 July 2019
Volume 29, Issue 3, May 2018
Previous Article Next Article

Abstract

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions. 

 

 

 

Cite this article as: Aygen B, Demir AM, Gümüş M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018; 29: 259-69.

Files
Full Text PDF
EISSN 2148-5607